Clinical Trial Update: Dupilumab on Airway Hyper-responsiveness and Ventilation Heterogeneity in Patients With Asthma. [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating dupilumab on airway hyper-responsiveness and ventilation heterogeneity in asthma patients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Dupilumab (dupilumab)

Snippet

Sponsor: McMaster University | Conditions: Asthma | Phase 3 | Status: COMPLETED